Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Lumateperone Monotherapy in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder (Bipolar Depression) or Major Depressive Disorder

    Summary
    EudraCT number
    		 2019-004440-29
    Trial protocol
    		 BG  
    Global end of trial date
    30 Nov 2022

    Results information
    Results version number
    		 v1(current)
    This version publication date
    27 Dec 2023
    First version publication date
    27 Dec 2023
    Other versions

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    ITI-007-403
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 NCT04285515
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    Intra-Cellular Therapies, Inc.
    Sponsor organisation address
    430 East 29th Street, New York, United States, 10016
    Public contact
    ITI Clinical Trials, Intra-Cellular Therapies, Inc., +1 646-440-9333, ITCIClinicalTrials@itci-inc.com
    Scientific contact
    ITI Clinical Trials, Intra-Cellular Therapies, Inc., +1 646-440-9333, ITCIClinicalTrials@itci-inc.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    15 Mar 2023
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    30 Nov 2022
    Global end of trial reached?
    Yes
    Global end of trial date
    30 Nov 2022
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary objective of this study is to confirm the efficacy of lumateperone 42 mg administered orally once daily compared with that of placebo as measured by mean change from baseline to Day 43 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score in patients with bipolar depression with mixed features or major depressive disorder with mixed features.
    Protection of trial subjects
    The study was conducted in accordance with the ethical principles that have their origins in the Declaration of Helsinki. The study complied with the ICH Guidance on General Considerations for Clinical Trials and GCP, as well as CFR Part 312.
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    07 Feb 2020
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Bulgaria: 167
    Country: Number of subjects enrolled
    United States: 167
    Country: Number of subjects enrolled
    Ukraine: 37
    Country: Number of subjects enrolled
    Russian Federation: 78
    Country: Number of subjects enrolled
    Serbia: 39
    Worldwide total number of subjects
    488
    EEA total number of subjects
    167
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    468
    From 65 to 84 years
    20
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 -

    Pre-assignment
    Screening details
    		 The Screening phase begins once the Informed Consent Form is signed. Patients are evaluated during the screening period lasting up to 2 weeks.

    Pre-assignment period milestones
    Number of subjects started
    		 731 [1]
    Number of subjects completed
    		 488

    Pre-assignment subject non-completion reasons
    Reason: Number of subjects
    		 Screen Failure: 243
    Notes
    [1] - The number of subjects reported to have started the pre-assignment period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
    Justification: Pre-assignment period includes all pts that are screened. Worldwide number enrolled are those patients that have been randomized.
    Period 1
    Period 1 title
    Overall Trial (overall period)
    Is this the baseline period?
    		 Yes
    Allocation method
    Randomised - controlled
    Blinding used
    		 Double blind
    Roles blinded
    		 Subject, Investigator, Monitor

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 Lumateperone 42mg
    Arm description
    		 -
    Arm type
    		 Experimental

    Investigational medicinal product name
    Lumateperone
    Investigational medicinal product code
    Other name
    ITI-007
    Pharmaceutical forms
    Capsule
    Routes of administration
    Oral use
    Dosage and administration details
    Once daily oral administration

    Investigational medicinal product name
    Lumateperone
    Investigational medicinal product code
    Other name
    ITI-007
    Pharmaceutical forms
    Capsule
    Routes of administration
    Oral use
    Dosage and administration details
    Once oral daily administration

    Arm title
    		 Placebo
    Arm description
    		 -
    Arm type
    		 Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule
    Routes of administration
    Oral use
    Dosage and administration details
    Once daily oral administration

    Number of subjects in period 1
    		Lumateperone 42mg Placebo
    Started
    243
    245
    Completed
    211
    217
    Not completed
    32
    28
         Physician decision
    1
    -
         Consent withdrawn by subject
    5
    11
         Adverse event, non-fatal
    10
    5
         Other
    1
    3
         Lost to follow-up
    9
    4
         Lack of efficacy
    2
    3
         Protocol deviation
    4
    2

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Lumateperone 42mg
    Reporting group description
    		 -

    Reporting group title
    Placebo
    Reporting group description
    		 -

    Reporting group values
    		 Lumateperone 42mg Placebo Total
    Number of subjects
    		 243 245 488
    Age categorical
    Units: Subjects
        In utero
    		 0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    		 0 0 0
        Newborns (0-27 days)
    		 0 0 0
        Infants and toddlers (28 days-23 months)
    		 0 0 0
        Children (2-11 years)
    		 0 0 0
        Adolescents (12-17 years)
    		 0 0 0
        Adults (18-64 years)
    		 231 237 468
        From 65-84 years
    		 12 8 20
        85 years and over
    		 0 0 0
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    		 42.7 ( 14.58 ) 43.4 ( 13.84 ) -
    Gender categorical
    Units: Subjects
        Female
    		 151 150 301
        Male
    		 92 95 187

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    Lumateperone 42mg
    Reporting group description
    		 -

    Reporting group title
    Placebo
    Reporting group description
    		 -

    Subject analysis set title
    Intent-to Treat
    Subject analysis set type
    		 Intention-to-treat
    Subject analysis set description
    • Intent-to-Treat (ITT) Analysis Set contains all patients who were randomized before Protocol Amendment 2.0 and all patients who were randomized after Protocol Amendment 2.0, who received at least 1 dose of study drug and who had a nonmissing (predose) baseline assessment and at least 1 nonmissing postbaseline assessment of MADRS total score

    Primary: Change from baseline to Day 43 in the Montgomery-Asberg Depression Rating Scale (MADRS) total score

    		 Close Top of page
    End point title
    		 Change from baseline to Day 43 in the Montgomery-Asberg Depression Rating Scale (MADRS) total score
    End point description
    End point type
    Primary
    End point timeframe
    Baseline to Day 43
    End point values
    		 Lumateperone 42mg Placebo
    Number of subjects analysed
    211
    219
    Units: unit(s)
        least squares mean (confidence interval 95%)
    -17.7 (-18.92 to -16.42)
    -12.1 (-13.34 to -10.86)
    Statistical analysis title
    		 Primary Efficacy Analysis
    Comparison groups
    Lumateperone 42mg v Placebo
    Number of subjects included in analysis
    430
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 < 0.0001
    Method
    		 Mixed models analysis
    Parameter type
    		 LS Mean Difference
    Point estimate
    -5.6
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -7.25
         upper limit
    		 -3.88
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.86

    Secondary: Change from baseline to Day 43 in the Clinical Global Impression-Severity Scale (CGI-S) total score

    		 Close Top of page
    End point title
    		 Change from baseline to Day 43 in the Clinical Global Impression-Severity Scale (CGI-S) total score
    End point description
    End point type
    Secondary
    End point timeframe
    Baseline to Day 43
    End point values
    		 Lumateperone 42mg Placebo
    Number of subjects analysed
    211
    219
    Units: Unit
        least squares mean (confidence interval 95%)
    -1.7 (-1.89 to -1.61)
    -1.1 (-1.26 to -0.98)
    Statistical analysis title
    		 Key Secondary Efficacy Analysis
    Comparison groups
    Placebo v Lumateperone 42mg
    Number of subjects included in analysis
    430
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 < 0.0001
    Method
    		 Mixed models analysis
    Parameter type
    		 LS Mean Difference
    Point estimate
    -0.6
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -0.82
         upper limit
    		 -0.44
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.1

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From the time the subject gives study-specific informed consent until the end of study procedures being completed.
    Assessment type
    		 Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    22.1
    Reporting groups
    Reporting group title
    Lumateperone 42mg
    Reporting group description
    		 Includes patients randomized to the Lumateperone 42 mg group and who received at least 1 dose of study drug.

    Reporting group title
    Placebo
    Reporting group description
    		 Includes patients randomized to the Placebo group and who received at least 1 dose of study drug.

    Serious adverse events
    		 Lumateperone 42mg Placebo
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 240 (0.00%)
    1 / 241 (0.41%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    0
    0
    Skin and subcutaneous tissue disorders
    Dermatitis
         subjects affected / exposed
    0 / 240 (0.00%)
    1 / 241 (0.41%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    		 Lumateperone 42mg Placebo
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    84 / 240 (35.00%)
    37 / 241 (15.35%)
    Nervous system disorders
    Headache
         subjects affected / exposed
    37 / 240 (15.42%)
    30 / 241 (12.45%)
         occurrences all number
    40
    33
    Somnolence
         subjects affected / exposed
    31 / 240 (12.92%)
    4 / 241 (1.66%)
         occurrences all number
    31
    4
    Dizziness
         subjects affected / exposed
    28 / 240 (11.67%)
    4 / 241 (1.66%)
         occurrences all number
    30
    4
    Gastrointestinal disorders
    Nausea
         subjects affected / exposed
    19 / 240 (7.92%)
    5 / 241 (2.07%)
         occurrences all number
    19
    5

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    02 Nov 2020
    -The addition of patients with major depressive disorder (MDD) to the study population and the addition of the inclusion criterion for all patients to meet the Diagnostic and Statistical Manual of Mental Disorder, 5th Edition (DSM-5) criteria for mixed features specific to the Bipolar I or II diagnosis or MDD diagnosis. -Increase in sample size.

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 04 20:44:31 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA